GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virpax Pharmaceuticals Inc (NAS:VRPX) » Definitions » Cash Ratio

Virpax Pharmaceuticals (Virpax Pharmaceuticals) Cash Ratio : 0.43 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Virpax Pharmaceuticals Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Virpax Pharmaceuticals's Cash Ratio for the quarter that ended in Mar. 2024 was 0.43.

Virpax Pharmaceuticals has a Cash Ratio of 0.43. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Virpax Pharmaceuticals's Cash Ratio or its related term are showing as below:

VRPX' s Cash Ratio Range Over the Past 10 Years
Min: 0.02   Med: 4.06   Max: 23.02
Current: 0.43

During the past 6 years, Virpax Pharmaceuticals's highest Cash Ratio was 23.02. The lowest was 0.02. And the median was 4.06.

VRPX's Cash Ratio is ranked worse than
84.75% of 1475 companies
in the Biotechnology industry
Industry Median: 3.03 vs VRPX: 0.43

Virpax Pharmaceuticals Cash Ratio Historical Data

The historical data trend for Virpax Pharmaceuticals's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virpax Pharmaceuticals Cash Ratio Chart

Virpax Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial 0.02 0.02 17.64 6.14 1.19

Virpax Pharmaceuticals Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.16 4.06 1.86 1.19 0.43

Competitive Comparison of Virpax Pharmaceuticals's Cash Ratio

For the Biotechnology subindustry, Virpax Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virpax Pharmaceuticals's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virpax Pharmaceuticals's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Virpax Pharmaceuticals's Cash Ratio falls into.



Virpax Pharmaceuticals Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Virpax Pharmaceuticals's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=9.142/7.694
=1.19

Virpax Pharmaceuticals's Cash Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash Ratio (Q: Mar. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=1.866/4.344
=0.43

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Virpax Pharmaceuticals  (NAS:VRPX) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Virpax Pharmaceuticals Cash Ratio Related Terms

Thank you for viewing the detailed overview of Virpax Pharmaceuticals's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Virpax Pharmaceuticals (Virpax Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1055 Westlakes Drive, Suite 300, Berwyn, PA, USA, 19312
Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.
Executives
Sheila Mathias officer: Chief Scientific Officer 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Vinay Shah officer: Chief Financial Officer C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Barbara Ruskin director C/O VIRPAX PHARMACEUTICALS, INC., 1055 WESTLAKES DRIVE, SUITE 300, BERWYN PA 19312
Jerrold Sendrow director C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Eric Floyd director C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Anthony P. Mack director, 10 percent owner, officer: Chief Executive Officer C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Michael F Dubin director C/O VIRPAX PHARMACEUTICALS, 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Vanila Singh director C/O BIODELIVERY SCIENCES INTERNATIONAL, 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Gary S Jacob director
Christopher Michael Chipman officer: Chief Financial Officer C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Jeffrey Gudin director, officer: Chief Medical Officer C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Thani Jambulingam director C/O VIRAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380
Gerald W Bruce officer: EVP, Commercial Operations NITROMED INC, 125 SPRING STREET, LEXINGTON MA 02421
Virpax Pharmaceuticals Llc 10 percent owner C/O VIRPAX PHARMACEUTICALS, INC., 1554 PAOLI PIKE #279, WEST CHESTER PA 19380